Michael Ackermann, Director at Tarsus Pharmaceuticals, Inc. (TARS), sold 200 shares at $25.03 ($5K) on 2021-10-08, disclosed to the SEC on 2021-10-12.
Scheduled sale ($5k) by Director under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| Filing → |
| TARS | SELL | 2021-11-03 | $300K | — | Filing → |
| TARS | SELL | 2021-10-14 | $267K | — | Filing → |
| TARS | SELL | 2021-09-03 | $294K | — | Filing → |